메뉴 건너뛰기




Volumn 20, Issue 9, 2004, Pages 1437-1445

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

Author keywords

Diabetes mellitus; Ezetimibe; Hypercholesterolemia; LDL C; Metabolic syndrome; Statin

Indexed keywords

AMINOTRANSFERASE; ANTIHYPERTENSIVE AGENT; APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; CERIVASTATIN; CREATINE KINASE; EZETIMIBE; FLUINDOSTATIN; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; PRAVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

EID: 5444270779     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079904X2321     Document Type: Article
Times cited : (91)

References (31)
  • 1
    • 0842277242 scopus 로고    scopus 로고
    • Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition
    • Grundy SM, Brewer Jr HB, Cleeman JI, Smith Jr SC, Lenfant C. Definition of metabolic syndrome: report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation 2004;109(3):433-8
    • (2004) Circulation , vol.109 , Issue.3 , pp. 433-438
    • Grundy, S.M.1    Brewer Jr., H.B.2    Cleeman, J.I.3    Smith Jr., S.C.4    Lenfant, C.5
  • 2
    • 0035897696 scopus 로고    scopus 로고
    • Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
    • Adult Treatment Panel III. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 2001;285(19):2486-97
    • (2001) J Am Med Assoc , vol.285 , Issue.19 , pp. 2486-2497
  • 3
    • 0029037649 scopus 로고
    • Pathophysiology of insulin resistance in human disease
    • Reaven GM. Pathophysiology of insulin resistance in human disease. Physiol Rev 1995;75(3):473-86
    • (1995) Physiol Rev , vol.75 , Issue.3 , pp. 473-486
    • Reaven, G.M.1
  • 4
    • 0027406191 scopus 로고
    • Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial
    • Stamler J, Vaccaro O, Neaton JD, Wentworth D. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993;16(2):434-44
    • (1993) Diabetes Care , vol.16 , Issue.2 , pp. 434-444
    • Stamler, J.1    Vaccaro, O.2    Neaton, J.D.3    Wentworth, D.4
  • 5
    • 0042665536 scopus 로고    scopus 로고
    • Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study
    • Sattar N, Gaw A, Scherbakova O, et al. Metabolic syndrome with and without C-reactive protein as a predictor of coronary heart disease and diabetes in the West of Scotland Coronary Prevention Study. Circulation 2003;108(4):414-9
    • (2003) Circulation , vol.108 , Issue.4 , pp. 414-419
    • Sattar, N.1    Gaw, A.2    Scherbakova, O.3
  • 6
    • 0346962890 scopus 로고    scopus 로고
    • The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
    • Girman CJ, Rhodes T, Mercuri M, et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004;93:136-41
    • (2004) Am J Cardiol , vol.93 , pp. 136-141
    • Girman, C.J.1    Rhodes, T.2    Mercuri, M.3
  • 7
    • 0032560807 scopus 로고    scopus 로고
    • Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction
    • Haffner SM, Lehto S, Ronnemaa T, Pyorala K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. New Engl J Med 1998;339(4):229-34
    • (1998) New Engl J Med , vol.339 , Issue.4 , pp. 229-234
    • Haffner, S.M.1    Lehto, S.2    Ronnemaa, T.3    Pyorala, K.4    Laakso, M.5
  • 8
    • 0037678289 scopus 로고    scopus 로고
    • Management of dyslipidemia in adults with diabetes
    • Haffner SM. Management of dyslipidemia in adults with diabetes. Diabetes Care 2003;26(Suppl 1):S83-S86
    • (2003) Diabetes Care , vol.26 , Issue.SUPPL. 1
    • Haffner, S.M.1
  • 9
    • 4344575902 scopus 로고    scopus 로고
    • European guidelines on cardiovascular disease prevention in clinical practice: Third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts)
    • De Backer G, Ambrosioni E, Borch-Johnsen K, J et al. European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 2003;10(4):S1-S10
    • (2003) Eur J Cardiovasc Prev Rehabil , vol.10 , Issue.4
    • De Backer, G.1    Ambrosioni, E.2    Borch-Johnsen, K.J.3
  • 10
    • 1242273622 scopus 로고    scopus 로고
    • Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: Findings in EUROASPIRE II
    • De Backer G. Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings in EUROASPIRE II. Atheroscler Suppl 2002;2(4):13-6
    • (2002) Atheroscler Suppl , vol.2 , Issue.4 , pp. 13-16
    • De Backer, G.1
  • 11
    • 0034723758 scopus 로고    scopus 로고
    • The lipid treatment assessment project (L-TAP): A multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals
    • Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med 2000;160(4):459-67
    • (2000) Arch Intern Med , vol.160 , Issue.4 , pp. 459-467
    • Pearson, T.A.1    Laurora, I.2    Chu, H.3    Kafonek, S.4
  • 12
    • 0001132313 scopus 로고    scopus 로고
    • Clinical reality of coronary prevention guidelines: A comparison of EUROASPIRE 1 and II in nine countries. EUROASPIRE I and II Group. European action on secondary prevention by intervention to reduce events
    • Clinical reality of coronary prevention guidelines: a comparison of EUROASPIRE 1 and II in nine countries. EUROASPIRE I and II Group. European Action on Secondary Prevention by Intervention to Reduce Events. Lancet 2001;357(9261):995-1001
    • (2001) Lancet , vol.357 , Issue.9261 , pp. 995-1001
  • 13
    • 0037524291 scopus 로고    scopus 로고
    • Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events
    • Foley KA, Simpson Jr RJ, Crouse III JR, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am J Cardiol 2003;92(1):79-81
    • (2003) Am J Cardiol , vol.92 , Issue.1 , pp. 79-81
    • Foley, K.A.1    Simpson Jr., R.J.2    Crouse III, J.R.3    Weiss, T.W.4    Markson, L.E.5    Alexander, C.M.6
  • 14
    • 0035881018 scopus 로고    scopus 로고
    • Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins
    • Andrews TC, Ballantyne CM, Hsia JA, Kramer JH. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111 (3):185-91
    • (2001) Am J Med , vol.111 , Issue.3 , pp. 185-191
    • Andrews, T.C.1    Ballantyne, C.M.2    Hsia, J.A.3    Kramer, J.H.4
  • 15
    • 0032168473 scopus 로고    scopus 로고
    • Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines
    • Frolkis JP, Zyzanski SJ, Schwartz JM, Suhan PS. Physician noncompliance with the 1993 National Cholesterol Education Program (NCEP-ATPII) guidelines. Circulation 1998;98(9):851-5
    • (1998) Circulation , vol.98 , Issue.9 , pp. 851-855
    • Frolkis, J.P.1    Zyzanski, S.J.2    Schwartz, J.M.3    Suhan, P.S.4
  • 16
    • 0034776367 scopus 로고    scopus 로고
    • Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function
    • van Heek M, Farley C, Compton DS, Hoos L, Davis HR. Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function. Br J Pharmacol 2001;134(2):409-17
    • (2001) Br J Pharmacol , vol.134 , Issue.2 , pp. 409-417
    • Van Heek, M.1    Farley, C.2    Compton, D.S.3    Hoos, L.4    Davis, H.R.5
  • 17
    • 0034003105 scopus 로고    scopus 로고
    • Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
    • van Heek M, Farley C, Compton DS, et al. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663. Br J Pharmacol 2000;129(8):1748-54
    • (2000) Br J Pharmacol , vol.129 , Issue.8 , pp. 1748-1754
    • Van Heek, M.1    Farley, C.2    Compton, D.S.3
  • 18
    • 10744221008 scopus 로고    scopus 로고
    • Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption
    • Altmann SW, Davis Jr HR, Zhu LJ, et al. Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption. Science 2004;303(5661):1201-4
    • (2004) Science , vol.303 , Issue.5661 , pp. 1201-1204
    • Altmann, S.W.1    Davis Jr., H.R.2    Zhu, L.J.3
  • 19
    • 0037504445 scopus 로고    scopus 로고
    • Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial
    • Ballantyne CM, Houri J, Notarbartolo A, et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 2003;107(19):2409-15
    • (2003) Circulation , vol.107 , Issue.19 , pp. 2409-2415
    • Ballantyne, C.M.1    Houri, J.2    Notarbartolo, A.3
  • 20
    • 0037111890 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia
    • Gagne C, Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol 2002;90(10):1084-91
    • (2002) Am J Cardiol , vol.90 , Issue.10 , pp. 1084-1091
    • Gagne, C.1    Bays, H.E.2    Weiss, S.R.3
  • 21
    • 0037441702 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia
    • Kerzner B, Corbelli J, Sharp S, A et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol 2003;91(4):418-24
    • (2003) Am J Cardiol , vol.91 , Issue.4 , pp. 418-424
    • Kerzner, B.1    Corbelli, J.2    Sharp, S.A.3
  • 22
    • 0344490262 scopus 로고    scopus 로고
    • Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: A prospective, randomized, double-blind trial
    • Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J 2003;24(8):717-28
    • (2003) Eur Heart J , vol.24 , Issue.8 , pp. 717-728
    • Melani, L.1    Mills, R.2    Hassman, D.3
  • 23
    • 0037132598 scopus 로고    scopus 로고
    • Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia
    • Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol 2002;40(12):2125-34
    • (2002) J Am Coll Cardiol , vol.40 , Issue.12 , pp. 2125-2134
    • Davidson, M.H.1    McGarry, T.2    Bettis, R.3
  • 24
    • 0027243348 scopus 로고
    • Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults
    • Adult Treatment Panel II. Summary of the second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. J Am Med Assoc 1993;269(23):3015-23
    • (1993) J Am Med Assoc , vol.269 , Issue.23 , pp. 3015-3023
  • 25
    • 0037407197 scopus 로고    scopus 로고
    • Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease
    • Nishizawa Y, Shoji T, Kakiya R, et al. Non-high-density lipoprotein cholesterol (non-HDL-C) as a predictor of cardiovascular mortality in patients with end-stage renal disease. Kidney Int Suppl 2003;(84):S117-S120
    • (2003) Kidney Int Suppl , Issue.84
    • Nishizawa, Y.1    Shoji, T.2    Kakiya, R.3
  • 26
    • 0032568089 scopus 로고    scopus 로고
    • Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy
    • Frost PH, Havel RJ. Rationale for use of non-high-density lipoprotein cholesterol rather than low-density lipoprotein cholesterol as a tool for lipoprotein cholesterol screening and assessment of risk and therapy. Am J Cardiol 1998;81(4A): 26B-31B
    • (1998) Am J Cardiol , vol.81 , Issue.4 A
    • Frost, P.H.1    Havel, R.J.2
  • 27
    • 0029832009 scopus 로고    scopus 로고
    • Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study
    • Lamarche B, Moorjani S, Lupien PJ, et al. Apolipoprotein A-I and B levels and the risk of ischemic heart disease during a five-year follow-up of men in the Quebec cardiovascular study. Circulation 1996;94(3):273-8
    • (1996) Circulation , vol.94 , Issue.3 , pp. 273-278
    • Lamarche, B.1    Moorjani, S.2    Lupien, P.J.3
  • 28
    • 0242442147 scopus 로고    scopus 로고
    • Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS)
    • Williams K, Sniderman AD, Sattar N, D'Agostino Jr R, Wagenknecht LE, Haffner SM. Comparison of the associations of apolipoprotein B and low-density lipoprotein cholesterol with other cardiovascular risk factors in the Insulin Resistance Atherosclerosis Study (IRAS). Circulation 2003;108(19):2312-6
    • (2003) Circulation , vol.108 , Issue.19 , pp. 2312-2316
    • Williams, K.1    Sniderman, A.D.2    Sattar, N.3    D'Agostino Jr., R.4    Wagenknecht, L.E.5    Haffner, S.M.6
  • 29
    • 0031861930 scopus 로고    scopus 로고
    • Plasma triglyceride as a risk factor for cardiovascular disease
    • Austin MA. Plasma triglyceride as a risk factor for cardiovascular disease. Can J Cardiol 1998;14(Suppl B):14B-17B
    • (1998) Can J Cardiol , vol.14 , Issue.SUPPL. B
    • Austin, M.A.1
  • 30
    • 0346996795 scopus 로고    scopus 로고
    • Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein
    • Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol 2003;92:1414-8
    • (2003) Am J Cardiol , vol.92 , pp. 1414-1418
    • Sager, P.T.1    Melani, L.2    Lipka, L.3
  • 31
    • 0037031061 scopus 로고    scopus 로고
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: A randomised placebo-controlled trial
    • MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7-22
    • (2002) Lancet , vol.360 , Issue.9326 , pp. 7-22


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.